ACCSCIENCE PUBLISHING

Artificial Intelligence in Health

PERSPECTIVE ARTICLE

Artificial intelligence for ophthalmic drug discovery and development: Capabilities, applications, and challenges

Siddharth Gandhi[1] **and Michael Balas**[2*]

[1]School of Medicine, Queen's University, Kingston, Ontario, Canada

[2]Department of Ophthalmology & Vision Sciences, University of Toronto, Toronto, Ontario, Canada

Abstract

The integration of artificial intelligence (AI) into ophthalmic drug discovery and development presents transformative opportunities to address the inherent complexities and challenges of creating targeted therapies for eye diseases. The ability of AI to process vast datasets can facilitate the discovery of novel drug candidates, improve predictions of drug efficacy and safety, and streamline the drug development pipeline. Applications can range from enhancing target identification and compound screening to refining predictive toxicology. However, challenges such as data limitations, computational demands, model interpretability, and ethical considerations remain. Despite these hurdles, the integration of AI with emerging technologies and its potential to optimize clinical trials signifies a new era of innovation in ophthalmology, emphasizing its critical role in addressing current challenges and advancing therapeutic development. In this paper, we explore the role of AI in ophthalmic drug discovery, highlighting its potential to address critical challenges in the field and delineating its impact across various stages of drug development.

Keywords: Ophthalmology; Artificial intelligence; Drug discovery; Drug development

***Corresponding author:**
Michael Balas
(michael.balas@mail.utoronto.ca)

Citation: Gandhi S, Balas M. Artificial intelligence for ophthalmic drug discovery and development: Capabilities, applications, and challenges. *Artif Intell Health*. 2024;1(3):26-30. doi: 10.36922/aih.3341

Received: April 1, 2024

Accepted: May 13, 2024

Published Online: July 22, 2024

1. Introduction

The field of ophthalmology encounters unique challenges in drug development stemming from the complexity of eye diseases and the necessity for highly targeted therapeutic interventions. Traditional drug discovery processes are often slow and costly, and they are hampered by high failure rates, particularly in predicting drug efficacy and safety within the context of eye diseases.[1] These challenges underscore the urgent need for innovative approaches to accelerate and refine drug discovery in ophthalmology.

Artificial intelligence (AI) is reshaping the frontier of drug discovery. By analyzing large datasets, AI can efficiently identify patterns and insights that may lead to the discovery of novel drug candidates, as well as enhance predictions of drug efficacy and toxicities. Moreover, AI can enhance our understanding of disease mechanisms, contribute to personalized medicine, and streamline drug development pipelines, thereby expediting the process, reducing costs, and ultimately increasing effectiveness.[2]

The integration of AI into ophthalmic drug discovery represents a convergence of technology and medicine that could significantly advance the treatment of eye diseases. By leveraging AI in target identification, compound screening, and predictive toxicology, researchers can overcome some of the traditional bottlenecks in the drug discovery pipeline, facilitating much-needed treatments for patients with eye diseases.[1] Beyond expediting the development of safe, effective, and targeted treatments, this integration may also enrich our understanding of ophthalmic disease processes. In this paper, we explore the role of AI in ophthalmic drug discovery, offering insights into its potential to address the critical challenges in the field.

2. AI in drug discovery

The discovery and validation of therapeutic targets are critical steps in the drug discovery pipeline. This process involves identifying molecular targets, such as proteins that play a key role in disease pathogenesis, and confirming their suitability for therapeutic intervention.[3] Traditional methods for target identification are often labor-intensive, time-consuming, and fraught with uncertainty. AI can analyze vast datasets from genomic, proteomic, and other multi-omic studies to uncover potential targets related to eye diseases more efficiently than traditional approaches.[3] Once potential targets are identified, AI can further assist in validating these targets by predicting their role in disease progression and response to therapeutic intervention, thus enhancing the specificity and effectiveness of drug development efforts in ophthalmology.[3]

After identifying possible therapeutic targets, the process of compound screening involves testing numerous agents for activity against the identified target. This phase also includes optimizing these agents to improve their efficacy, safety profile, and pharmacokinetic properties.[2] AI has the potential to significantly accelerate this phase using models that predict compound-target interactions, thereby narrowing down the vast library of potential compounds to those most likely to exhibit desired therapeutic effects. In addition, AI-driven models can simulate the molecular docking process and provide predictions on how different compounds will bind to target proteins.[4] This not only accelerates the screening process but also enhances the precision of compound selection for further development. Moreover, AI can optimize compound structures by predicting modifications that enhance drug-like properties, ensuring that the most promising candidates are advanced to the next stages of drug development with optimized profiles for effectiveness and safety.[2]

Finally, predictive toxicology is essential in assessing the safety profile of drug candidates before they advance to clinical trials, given the substantial costs associated with late-stage drug development failures due to unforeseen toxicity.[5] AI models, especially those trained on extensive databases of chemical structures and their associated toxicological profiles, offer high accuracy in predicting the toxicity of new compounds.[5] By integrating data from various sources, including preclinical studies and known drug safety profiles, AI can forecast adverse effects and serve as an early warning system to prioritize compounds with favorable safety profiles.[6] This capability not only reduces the risk of late-stage failures but also ensures a more efficient allocation of resources toward candidates with the highest likelihood of success in treating ophthalmic conditions. It is important to note that while specific applications of AI models in ophthalmology are still emerging, the theoretical and operational frameworks established in other therapeutic areas provide a promising foundation for their application in ocular drug development.

3. Current applications and case studies in ophthalmology

As patients' adherence to dosing regimens (eye drops) and frequent intraocular injections can be substantial barriers to effective chronic ocular disease management, sustained drug delivery strategies can be helpful.[7] However, as these sustained therapeutic methods are traditionally achieved by implantable devices, there is a risk of excipient material buildup, the need for device removal, potential adverse reactions, etc.[7] An alternative approach would be to increase the retention time and therapeutic effects of drugs in the eye without using implants, as attempted by Hsueh *et al.*[7] As ocular melanin has a low turnover rate, they hypothesized that a melanin-binding peptide could be conjugated to small-molecule drugs to increase their retention time and therapeutic effect. Since incorporating multiple functions into a single peptide sequence is challenging, they used machine learning methods to help engineer peptide sequences that could simultaneously provide these desired functions. As a result, their engineered peptide exhibited increased cell-penetrating properties and high melanin binding capacity while demonstrating low cytotoxicity. They tested these compounds in rabbits and discovered that their multifunctional peptide greatly enhanced the pharmacokinetics and pharmacodynamics of brimonidine when compared to normal use. In this work, machine learning played a key role in identifying important variables for desired peptide function, refining peptide design, and achieving desired therapeutic goals.

The application of AI extends beyond enhancing drug delivery systems to revolutionizing our approach to disease management strategies, including neurodegenerative ocular diseases. There is a plethora of neurodegenerative conditions that can cause damage to the optic nerve.[8] One of the primary pathophysiological mechanisms of action involves the damage of retinal ganglion cell (RGC) axons.[8] There is emerging evidence suggesting that axonal damage can initiate RGC death through reactive oxygen species (ROS), which in turn increases disulfide bond formation between cysteine side chains to cause further cellular damage.[8] Redox-active phosphine-borane complexes have been proposed as protective molecules that can activate cellular pathways to prevent these disulfide bonds from forming.[8] However, limited pharmacological data exists for these compounds. To resolve this issue, Remtulla *et al.*[8] trained neural networks on features such as cellular permeability, oral absorption, blood–brain barrier permeability, and serum protein binding to reliably predict the pharmacokinetics of boron-containing compounds. Their results revealed that phosphine-boron compounds met the necessary pharmacokinetic profile to function as orally active drug candidates. Ultimately, this study underscores the innovative use of machine learning in evaluating the pharmacokinetics of emerging compounds, such as phosphine-borane complexes, advancing their potential as neuroprotective agents against RGC damage. It exemplifies the ability to generate new perspectives in ocular pharmacology using pre-existing data and AI algorithms.

4. Challenges and limitations

Despite the promising advancements and successful applications of AI in ophthalmologic drug discovery, several challenges and limitations remain that require acknowledgment and resolution. First and foremost, the quality and quantity of data available for AI models significantly influence their performance and reliability.[9] In the realm of ophthalmology, high-quality, diverse, and annotated datasets, especially from clinical settings, are often scarce or fragmented.[9] This limitation can lead to biases in AI models, reducing their generalizability and accuracy when applied to broader, more diverse populations.

Furthermore, the computational resources required for AI research are substantial. The processing of large datasets and the training of sophisticated models necessitate advanced hardware and significant computational power, which can be a barrier for institutions with limited resources.[10] This technological and financial barrier may lead to disparities in research advancements and the adoption of AI technologies across different regions and institutions.

Another significant challenge is the interpretability of AI models, particularly those based on deep learning algorithms. These models are often described as "black boxes" due to their opaque decision-making processes, which are difficult for humans to comprehend.[11] This lack of transparency can hinder the trust and acceptance of AI-driven discoveries among clinicians, researchers, and regulatory bodies, which is critical for translating AI discoveries into practical therapeutic interventions. To address these challenges, the current strategies focus on the development of explainable AI methods, such as feature importance scores and rule-based decision trees, designed to demystify AI decisions and enhance model transparency. In addition, integrating domain-specific knowledge and employing hybrid models that combine deep learning with interpretable statistical methods are proving crucial in improving both the interpretability and reliability of these systems. Ensuring robustness and generalization through rigorous testing, coupled with proactive stakeholder engagement, is essential to validating and gaining acceptance for AI technologies in clinical settings.

The integration of AI into drug discovery also presents ethical and regulatory challenges. The use of patients' data raises privacy concerns, requiring stringent data protection measures and ethical oversight to ensure patient confidentiality and consent.[3] Moreover, regulatory frameworks for AI-assisted drug discovery and development are still in their infancy, lacking clear guidelines for validation, approval, and oversight of AI-driven methodologies. This regulatory uncertainty can delay the adoption and application of AI technologies in ophthalmology drug discovery.

5. Future direction

The integration of AI into ophthalmologic drug discovery marks a new era of medical innovation and operational efficiency, addressing longstanding challenges and opening new avenues for therapeutic development. Looking ahead, several research objectives are set to further leverage the capabilities of AI systems. Among these, a key goal will involve employing these technologies to enhance our understanding of complex eye diseases at the molecular level. Future efforts are likely to focus on developing more sophisticated algorithms that can process and analyze the increasingly large and complex datasets generated by biomedical research.[9] This will not only improve the accuracy of target identification and validation but also enable the discovery of novel biomarkers and therapeutic targets.[2]

Another promising direction involves the integration of AI with other emerging technologies, such as gene editing and stem cell therapy.[12] By combining AI's predictive and analytical capabilities with these novel therapeutic approaches, researchers can accelerate the development of personalized medicine strategies for ophthalmic diseases.

Moreover, AI is set to play a crucial role in overcoming the challenges associated with the clinical trial phase of drug development.[13] By predicting patient responses to potential treatments and identifying the most suitable candidates for participation in trials, AI can streamline the process of participant recruitment. This would, in turn, lead to faster, more cost-effective trials that also enable researchers to fine-tune dosage and treatment protocols earlier, reducing the probability of unforeseen adverse reactions and late-stage trial failures.[13]

6. Conclusion

The integration of AI into ophthalmic drug discovery and development represents a paradigm shift, offering novel approaches to longstanding challenges in this field. Using AI in target identification, compound screening, and predictive toxicology, we are on the brink of making substantial progress in the treatment of eye diseases. The successful applications and case studies discussed underscore AI's potential to enhance drug delivery systems, refine disease management, and expedite drug development. However, addressing challenges and limitations, including data quality, computational resource requirements, model interpretability, and regulatory issues, is paramount to fully realizing its transformative potential. Nonetheless, the continued evolution of AI technologies, coupled with their integration into emerging therapeutic modalities, is likely to pave the way for advancements that will redefine our approach to treating ophthalmic diseases, ultimately improving patient outcomes and quality of life.

Acknowledgments

None.

Funding

None.

Conflict of interest

The authors declare that they have no competing interests.

Author contributions

Conceptualization: Michael Balas
Writing – original draft: Siddharth Gandhi
Writing – review & editing: All authors

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Availability of data

Not applicable.

References

1. Wang N, Zhang Y, Wang W, *et al*. How can machine learning and multiscale modeling benefit ocular drug development? *Adv Drug Deliv Rev*. 2023;196:114772.

   doi: 10.1016/j.addr.2023.114772

2. Paul D, Sanap G, Shenoy S, Kalyane D, Kalia K, Tekade RK. Artificial intelligence in drug discovery and development. *Drug Discov Today*. 2021;26(1):80-93.

   doi: 10.1016/j.drudis.2020.10.010

3. Pun FW, Ozerov IV, Zhavoronkov A. AI-powered therapeutic target discovery. *Trends Pharmacol Sci*. 2023;44(9):561-572.

   doi: 10.1016/j.tips.2023.06.010

4. Crampon K, Giorkallos A, Deldossi M, Baud S, Steffenel LA. Machine-learning methods for ligand-protein molecular docking. *Drug Discov Today*. 2022;27(1):151-164.

   doi: 10.1016/j.drudis.2021.09.007

5. Wang MWH, Goodman JM, Allen TEH. Machine learning in predictive toxicology: Recent applications and future directions for classification models. *Chem Res Toxicol*. 2021;34(2):217-239.

   doi: 10.1021/acs.chemrestox.0c00316

6. Yang S, Kar S. Application of artificial intelligence and machine learning in early detection of adverse drug reactions (ADRs) and drug-induced toxicity. *Artif Intell Chem*. 2023;1(2):100011.

   doi: 10.1016/j.aichem.2023.100011

7. Hsueh HT, Chou RT, Rai U, *et al*. Machine learning-driven multifunctional peptide engineering for sustained ocular drug delivery. *Nat Commun*. 2023;14(1):2509.

   doi: 10.1038/s41467-023-38056-w

8. Remtulla R, Das SK, Levin LA. Predicting absorption-distribution properties of neuroprotective phosphine-borane compounds using *in silico* modeling and machine learning. *Molecules*. 2021;26(9):2505.

   doi: 10.3390/molecules26092505

9. Li Z, Wang L, Wu X, *et al*. Artificial intelligence in ophthalmology: The path to the real-world clinic. *Cell Rep Med*. 2023;4(7):101095.

   doi: 10.1016/j.xcrm.2023.101095

10. Jia Z, Chen J, Xu X, *et al*. The importance of resource awareness in artificial intelligence for healthcare. *Nat Mach*

Intell. 2023;5(7):687-698.

doi: 10.1038/s42256-023-00670-0

11. Balagurunathan Y, Mitchell R, El Naqa I. Requirements and reliability of AI in the medical context. *Phys Med*. 2021;83:72-78.

    doi: 10.1016/j.ejmp.2021.02.024

12. Nosrati H, Nosrati M. Artificial intelligence in regenerative medicine: Applications and implications. *Biomimetics (Basel)*. 2023;8(5):442.

    doi: 10.3390/biomimetics8050442

13. Zhang B, Zhang L, Chen Q, Jin Z, Liu S, Zhang S. Harnessing artificial intelligence to improve clinical trial design. *Commun Med* (*Lond*). 2023;3(1):191.

    doi: 10.1038/s43856-023-00425-3